XBiotech (XBIT) Revenue (2020 - 2022)

XBiotech (XBIT) posted quarterly Revenue of $300000.0 for Q4 2022, down 82.14% quarter-over-quarter from $1.7 million in Q3 2022.

XBiotech (XBIT) Revenue (2020 - 2022) Analysis & Trends

XBiotech's Revenue history runs 3 years deep, the most recent figure standing at $300000.0 for Q4 2022.

In Q4 2022, Revenue changed N/A year-over-year to $300000.0; the TTM figure through Sep 2023 stood at $300000.0 (down 96.35% YoY), while the FY2022 annual figure was $4.0 million, down 78.2% from the prior year.
Revenue for Q4 2022 stood at $300000.0, down from $1.7 million in the prior quarter.
The five-year high for Revenue was $15.5 million in Q2 2020, with the low at -$34.2 million in Q4 2020.
The 3-year median for Revenue is $4.5 million (2021), against an average of $2.0 million.
The sharpest annual moves came in 2021 and 2022: Revenue tumbled 57.16% in 2021, then tumbled 89.69% in 2022.
XBiotech's Revenue stood at -$34.2 million in 2020, then jumped by 113.2% to $4.5 million in 2021, then slumped by 93.36% to $300000.0 in 2022.
Business Quant data shows XBIT's Revenue at $300000.0 in Q4 2022, $1.7 million in Q3 2022, and $1.5 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.52 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	145.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.71 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.29 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	425.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	674.14 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.06 Bn
10	XBiotech	68.90 Mn	68.90 Mn	-	-

Download Data